ABIVAX Société Anonyme reported €8.4M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €8.4M (to Q3 2025). Net income: −€336M, trailing twelve months to Q4 2025. Free cash flow: −€161M, trailing twelve months to Q4 2025. Operating margin: −3487%, trailing twelve months to Q3 2025.

ABVXABIVAX Société Anonyme

Healthcare

$88.10+7.0% 1Y

$88.10

$72.5052 weeks$145.31

ABVX as reported

ABIVAX Société Anonyme reported €8.4M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

€8.4M

Revenue, trailing twelve months · to Q3 2025 · every figure below is as filed, with no scoring applied

Net income: −€336M
Net income · trailing twelve months to Q4 2025
Free cash flow: −€161M
Free cash flow · trailing twelve months to Q4 2025
Operating margin: −3487%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for ABVX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€8.4M	n/a	Q3 2025
Net income	−€336M	n/a	Q4 2025
EPS	−€4.71	n/a	Q4 2025
Operating margin	−3487%	n/a	Q3 2025
Net margin	−4530%	n/a	Q3 2025
ROE	773%	n/a	Q4 2025
ROA	−94%	n/a	Q4 2025
Free cash flow	−€161M	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.